Serum lipoprotein(a) and high sensitivity C reactive protein levels in Saudi patients with type 2 diabetes mellitus and their relationship with glycemic control

To study serum lipoprotein(a) [Lp(a)] and high sensitivity C reactive protein (hsCRP) levels in Saudi patients with type 2 diabetes mellitus (DM) and their relationship with glycemic control. Materials and methods: A total of 201 subjects were selected for the study. The final selection included 103 patients with type 2 DM (64 males and 39 females) and 98 healthy control subjects (58 males and 40 females). Fasting venous blood samples were analyzed for glucose, glycosylated hemoglobin (HbA1c), lipids, Lp(a), and hsCRP levels. Results: Subjects with poor glycemic control showed significantly higher levels of fasting blood glucose levels (10.29 ± 3.56 vs. 7.05 ± 1.64, P = 0.0001) and HbA1c (9.72 ± 2.54 vs. 6.56 ± 0.51, P = 0.0001). Moreover, subjects with poor glycemic control were more obese than those with good glycemic control (BMI 30.63 ± 5.32 vs. 28.52 ± 4.93 P = 0.04010). It was observed that the diabetics with poor glycemic control had significantly higher levels of serum triglycerides (2.32 ± 1.26 vs. 1.67 ± 1.37, P = 0.0426), and hsCRP (5.16 ± 3.29 vs. 3.97 ± 2.5, P = 0.0423) compared with the good glycemic control group. While the difference for TC, LDL, HDL, and Lp(a) was nonsignificant, significant positive correlations were observed between HbA1c, BMI (r = 0.247, P = 0.038), TG (r = 0.247, P = 0.044), and hsCRP (r = 0.326, P = 0.006). Conclusion: Diabetic patients have higher levels of hsCRP and Lp(a) than healthy individuals. Diabetic patients with poor glycemic control have significantly higher hsCRP levels compared to those with good glycemic control. However, there is no effect of glycemic control on Lp(a) levels.

Anahtar Kelimeler:

Key words: Type 2 diabetes mellitus, glycemic control, high sensitivity C reactive protein, lipoprotein(a)

Serum lipoprotein(a) and high sensitivity C reactive protein levels in Saudi patients with type 2 diabetes mellitus and their relationship with glycemic control

Keywords:

Key words: Type 2 diabetes mellitus, glycemic control, high sensitivity C reactive protein, lipoprotein(a),

PDF

___

1. Khaw KT, Wareham N. Glycated hemoglobin as a marker of cardiovascular risk. Curr Opin Lipidol 2006; 17: 637–43.
2. Farmer JA. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diab Rep 2008; 8: 71–7.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12.
4. Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D et al. Relation of clinical benefit of raising highdensity lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol 2009 1; 103: 41–5.
5. Merkel M. Diabetic dyslipoproteinemia: beyond LDL. Dtsch Med Wochenschr 2009; 134: 1067–73.
6. Er Öztaş Y, Özdöl Ç, Karaca L. Plasma LDL subtype distribution in patients with or without coronary stenosis. Turk J Med Sci 2011; 41: 959–964.
7. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R et al. American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114–26.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10- year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.
9. Gambhir JK, Kaur H, Prabhu KM, Morrisett JD, Gambhir DS. Association between lipoprotein(a) levels, apo(a) isoforms and family history of premature CAD in young Asian Indians. Clin Biochem 2008; 41: 453–8.
10. de Brouckère V, Liénart F, Ducobu J. New data about lipoprotein(a): a curious molecule or a causal cardiovascular risk factor? Rev Med Brux 2010; 31: 171–6.
11. Habib SS. Lipoprotein(a). The bad cholesterol. Saudi Med J 2004; 25: 429–33.
12. Anuurad E, Enkhmaa B, Berglund L. Enigmatic role of lipoprotein(a) in cardiovascular disease. Clin Transl Sci 2010; 3: 327–32.
13. Habib SS, Abdel-Gader AM, Kurdi MI, Al-Aseri Z, Soliman MM. Lipoproteina(a) is a feature of the presence, diffuseness, and severity of coronary artery disease in Saudi population. Saudi Med J 2009; 30: 346–52.
14. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129–38.
15. Pfutzner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006; 8: 28–36.
16. Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, Zhang JS et al. Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2006; 20: 5–27.
17. Vergès B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005; 31: 429–39.
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33: S62–S69.
19. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. Circulation 2003; 107: 499–511.
20. Everett BM, Kurth T, Buring JE, Ridker PM. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women. J Am Coll Cardiol 2006; 48: 2235–42.
21. Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006; 114: 127–34.
22. Roopakala MS, Pawan HR, Krishnamurthy U, Wilma Delphine Silvia CR, Eshwarappa M, Prasanna Kumar KM. Evaluation of high sensitivity creactive protein and glycated hemoglobin levels in diabetic nephropathy. Saudi J Kidney Dis Transpl 2012; 23: 286–9.
23. Klaya F, Durlach V, Bertin E, Monier F, Monboisse JC, Gillery P. Evaluation of serum glycated lipoprotein (a) levels in noninsulin-dependent diabetic patients. Clin Biochem 1997; 30: 227–30.
24. Maca T, Mlekusch W, Doweik L, Budinsky AC, Bischof M, Minar E et al. Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease. Eur J Clin Invest 2007; 37: 180–6.
25. Stolinski M, Alam S, Jackson NC, Shojaee-Moradie F, Pentecost C, Jefferson W et al. Effect of 6-month supervised exercise on low-density lipoprotein apolipoprotein B kinetics in patients with type 2 diabetes mellitus. Metabolism 2008; 57: 1608–14.
26. Kadoglou NP, Iliadis F, Sailer N, Athanasiadou Z, Vitta I, Kapelouzou A et al. Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Metabolism 2010; 59: 599–607.
27. Alam S, Stolinski M, Pentecost C, Boroujerdi MA, Jones RH, Sonksen PH et al. The effect of a six-month exercise program on very low-density lipoprotein apolipoprotein B secretion in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 688–94.
28. Alsaeid M, Qabazard M, Shaltout A, Sharma PN. Impact of glycaemic control on serum lipoprotein(a) in Arab children with type 1 diabetes. Pediatr Int 2001; 43: 246–50.
29. Smaoui M, Hammami S, Chaaba R, Attia N, Hamda KB, Masmoudi AS et al. Lipids and lipoprotein(a) concentrations in Tunisian type 2 diabetic patients; Relationship to glycemic control and coronary heart disease. J Diabetes Complications 2004; 18: 258–63.
30. Çetin İ, Yıldırım B, Şahin Ş, Şahin İ, Etikan İ. Serum lipid and lipoprotein levels, dyslipidemia prevalence, and the factors that influence these parameters in a Turkish population living in the province of Tokat. Turk J Med Sci